Chemotherapy Or No Chemotherapy – CanAssist Breast Helps You DecideWhat comes to your mind when you think about breast cancer? It would most probably be ‘chemotherapy,’ ‘fear of a long process of treatment,’ ‘high costs,’ the fear of cancer coming back, and so on. These thoughts can be controlled with the right knowledge and right breast cancer treatments.
Researchers and oncologists have made new and promising forms of treatment for breast cancer. It’s time to personalize your treatment!
Our test classiﬁes patients as ‘low-risk’ or ‘high-risk’ based on the patient’s breast cancer recurrence risks over five years. The clear-cut test result provides doctors with additional information that can be used for treatment planning.
CanAssist Breast is a test that helps to plan the ideal treatment by predicting the breast cancer recurrence risk within five years of surgery. The risk of recurrence is lesser in early-stage breast cancer (Stage 1 and Stage 2), and hence, it is important for doctors and the patients to plan out a suitable course of treatment based on the breast cancer recurrence risk score.
Until a few years back, oncologists and clinicians were deciding cancer treatments based on age, tumor size, node status, grade, ER, PR and HER2 status. OncoStem Diagnostics realized there was a gap in the decision-making paradigm and understanding the tumor biology to comprehend the cancer progression and its aggressiveness would significantly change treatments depending on an individual’s tumor biology.
Tests similar to CanAssist Breast have been based on genomic analysis, whereas CanAssist Breast involves proteomics analysis. The genomics method considers genes of interest in the genome of a cell, whereas CanAssist Breast’s proteomics technique studies the proteins of interest produced by the cell. A 5-year study by OncoStem Diagnostics, recently published online, explains the detailed analysis and results that lead to the test, CanAssist Breast.
Your tumor is different, just like you are, as an individual.
Doctors and oncologists have to know as much possible about your tumor for optimal and ideal treatment.
Artificial intelligence and machine learning is an emerging approach in the healthcare sector including the treatment of breast cancer. CanAssist Breast is the first such test developed in India, specifically for Indian patients. It determines the tumor’s biochemical fingerprint and assesses its aggressiveness. Assessing the tumor biology in detail, the test considers five key biomarkers that are involved in recurrence-related pathways in the cell. Based on this combined analysis performed by proteomics-based technology, the information is then assessed by a statistical algorithm that provides a score between 0 and 100 – whether the patient is at low-risk or high-risk for cancer recurrence. A ‘CAB risk score’ less than 15.5 indicates a low-risk. Depending on each patient’s unique CAB risk score, the doctors can thus plan an ideal treatment tailored to an individual’s patient.
A decision that doctors and patients must make:
‘Fear’ is the most shared and challenging emotion that cancer brings with it. However, fearful a patient might be; it is essential for the patients to know and consider that their treatment can be different from that of the other patients.
Knowing who is eligible for the CanAssist-Breast test can help both patients and doctors. ‘
The patients must meet the below criteria to take CanAssist Breast:
- Patients with early-stage, invasive breast cancer
- Patients with hormone receptor-positive (“ER+ and/or PR+”) and HER2- negative disease
- Lymph node-negative or up to 3 lymph node-positive
- Patients should not have gone through neo-adjuvant chemotherapy
In India alone, 150,000 women are diagnosed with breast cancer every year. Of these, around 50 percent fall in the early-stage breast cancer category and a majority of them are eligible for this test.
Take your decision together
If you or someone among your friends or family are going through breast cancer (early-stage), you must consider taking CanAssist Breast before starting the treatment. If you are an oncologist or a doctor, maybe your patients could avoid the unnecessary treatments and the side effects most usually associated with chemotherapy.
Doctors must suggest the test to their eligible patients and patients must ask their doctors about the test score and personalize their treatment accordingly.
Want to know more about CanAssist Breast? Get in touch with us.
CanAssist Breast has helped her save money that she would have otherwise spent on chemotherapy.
It is essential that along with awareness about symptoms, early diagnosis, and the benefits of early treatment, patients are aware of all the new treatment options. With rising technology and advancement in the field of medical science, there are numerous alternatives to treatments.
Here’s a real experience of Ritu Misra (name changed on request) who was able to avoid chemotherapy only because she was aware of the options available to her.
Ritu, a resident of Gwalior, has always maintained a habit of getting annual health checkups. Her life took a difficult turn a year back when she went for an annual medical check-up. Scans revealed a shadow in her left breast. Upon further investigation, it was clear that she had stage 1 breast cancer. She underwent an operation to remove the tumor.
However, Ritu decided to find out more about breast cancer recurrence risk and understand all the other options available for her. Upon meeting a few specialists and doing her own research, she came to know that personalized treatment is possible for breast cancer. Upon further research, she came to know about CanAssist-Breast, a risk prediction test for early-stage breast cancers.
“My search for treatment options lead me to reading about personalized treatments. I’m glad I chose to explore alternatives.”
Some of her research findings strengthened her confidence in personalized medicine:
- Personalized treatment is a targeted approach to individual patient’s medical situations.
- Each patient’s condition is different and a one-size-fits-all method is impractical.
- Personalized treatment has the potential to avoid over and under treatment.
Ritu wanted to go ahead with the test but, was not sure about the costs. Like Ritu, most people who are newly introduced to breast cancer recurrence risk test worry about the costs involved and end up assuming that it would be expensive. However, CanAssist Breast shatters those misconceptions.
- CanAssist Breast is one among the affordable options when compared to similar tests that are available in the west.
- The test doesn’t involve any extra interference with the patient as it is conducted on the tumor sample which is already removed during the surgery.
- CanAssist Breast test costs INR 60,000 compared to similar tests that cost in lakhs.
- Getting this test done might mean that the patient can avoid the costs of chemotherapy if they are not at a high risk of recurrence of cancer. Each session of chemotherapy could cost as much as this test costs or more and a patient might need five to ten lakhs for complete chemotherapy sessions.
According to a study, lack of early diagnosis of breast cancer may kill 76,000 Indian women a year by 2020.
Personalized medicine plays a vital role in the treatment of early-stage breast cancer. Moreover, technology aided diagnosis and treatment of breast cancer have huge benefits in a country like India, where incidences of breast cancer are rising.
Your timely action can save you from the hassles of Chemotherapy. Consult your doctor and opt for CanAssist Breast to know breast cancer recurrence risk and plan your treatment.